Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial

Table 1 Baseline clinical and biochemical parameters of the randomized patients n (%)

	Curcumin group (n = 29)	Placebo group (n = 33)
Age (yr)	36 ± 12	34 ± 7
Sex (females)	13 (44.83)	8 (24.24)
Weight (kg)	55.1 ± 10.0	55.7 ± 11.7
BMI (kg/m2)	20.8 ± 3.1	20.5 ± 3.3
Disease duration (yr)	3.83 ± 4.00	3.64 ± 2.59
Disease extent
E3 (pancolitis)	7 (25.9)	6 (20.7)
E2 (left sided colitis)	17 (58.6)	21 (63.6)
E1 (proctitis)	3 (11.1)	2 (6.90)
Current smoking	5 (17.24)	4 (14.81)
Current alcohol use	3 (10.34)	4 (14.81)
Hemoglobin (g/dL)	12.12 ± 2.76	13.35 ± 1.72
Total leukocyte count (per cubic millimeter)	8586 ± 2306	8221 ± 2104
Platelet count(× 1000/mm3)	256.25 ± 131.98	257.53 ± 113.01
ESR (mm/1st h)	3 ± 2	4 ± 3
Urea (mg/dL)	22.0 ± 5.2	21.5 ± 5.2
Creatinine (mg/dL)	0.84 ± 0.26	1.19 ± 1.69
Potassium (meq/L)	4.41 ± 0.33	4.26 ± 0.78
Bilirubin (mg/dL)	0.7 ± 0.2	0.6 ± 0.1
Aspartate aminotransferase (U/L)	28 ± 6	30 ± 8
Alanine aminotransferase(U/L)	26 ± 9	28 ± 19
Total protein (g/L)	8.0 ± 0.2	7.9 ± 0.8
Albumin (g/L)	4.4 ± 0.5	4.5 ± 0.3
Current treatment
5-ASA	29 (100)	33 (100)
Steroids	0	0
Azathioprine	2 (6.9)	2 (6.2)
Rectal steroids	0	0
Mesalamine enema	0	0

Data are given as mean ± SD. 5-ASA: 5-aminosalicylates; BMI: Body mass index; ESR: Erythrocyte sedimentation rate.